MNM177 is a novel drug target linked to DNA damage response and replication stress pathways. Inhibition of MNM177 in tumors with genomic instability leads to the death of cancer cells. MNM177 was discovered in thousands of real patients’ data via our ARETEAI platform.
By analysing data from tumor genomes, the platform has identified patterns indicating the molecular pathway that the tumors with elevated replication stress are addicted to. MNM177 is the first-in-class drug target identified using such a deconvoluting approach. The MNM177 inhibitor has the potential for both combination therapy and monotherapy (as a single agent it could even surpass PARP inhibitors due to its essential role in Microhomology-Mediated End Joining (MMEJ)).
Target Discovery
Lead Identification
IND Enabling
Phase I - Clinical trials
MNM177
MNM391
MNM825
MNM177 first indication: breast.
MNM177 can be used in replication stress-high tumors.
Most tumors have an elevated level of replication stress, giving MNM177 a broad range of therapeutic indications.
ARETEAI
PATHWAY DECONVOLUTION FROM GENOMIC PATTERNS, AI-driven drug target platform
Drug target discovery
Predictive algorithms
Identify tumor addiction and cohort selection
In Vitro & In Vivo Research Laboratory
Drug target candidates are extensively validated in our Research Laboratory.
Bioanalytical and cell-based assays
X-ray crystallography
Cell cultures and animal models
Pre-clinical research
Predictive algorithms for precision medicine
We also develop predictive algorithms that stratify cancer patients for targeted therapies. These algorithms predict a drug response based on tumor molecular patterns.
Our AI-discovered algorithms for therapy response prediction
